WoundReference improves clinical decisions
 Choose the role that best describes you
Bianchi C, Cazzell S, Vayser D, Reyzelman AM, Dosluoglu H, Tovmassian G, EpiFix VLU Study Group., et al.
International wound journal. Date of publication 2018 Feb 1;volume 15(1):114-122.
1. Int Wound J. 2018 Feb;15(1):114-122. doi: 10.1111/iwj.12843. Epub 2017 Oct 11. A multicentre randomised controlled trial evaluating the efficacy of dehydrated human amnion/chorion membrane (EpiFix® ) allograft for the treatment of venous leg ulcers. Bianchi C(1), Cazzell S(2), Vayser D(3), Reyzelman AM(4), Dosluoglu H(5), Tovmassian G(6); EpiFix VLU Study Group. Author information: (1)Department of Surgery, Loma Linda University Medical Center, Loma Linda, CA, USA. (2)Limb Preservation Platform, Inc, Fresno, CA, USA. (3)ILD Research Center, San Diego, CA, USA. (4)Center for Clinical Research, Inc, San Francisco, CA, USA. (5)VA Western New York Healthcare System, Buffalo, NY, USA. (6)Center for Clinical Research, Inc. Sacramento Foot and Ankle Center, Sacramento, CA, USA. A randomised, controlled, multicentre clinical trial was conducted to evaluate the efficacy of dehydrated human amnion/chorion membrane (EpiFix) allograft as an adjunct to multilayer compression therapy for the treatment of non-healing full-thickness venous leg ulcers. We randomly assigned 109 subjects to receive EpiFix and multilayer compression (n = 52) or dressings and multilayer compression therapy alone (n = 57). Patients were recruited from 15 centres around the USA and were followed up for 16 weeks. The primary end point of the study was defined as time to complete ulcer healing. Participants receiving weekly application of EpiFix and compression were significantly more likely to experience complete wound healing than those receiving standard wound care and compression (60% versus 35% at 12 weeks, P = 0·0128, and 71% versus 44% at 16 weeks, P = 0·0065). A Kaplan-Meier analysis was performed to compare the time-to-healing performance with or without EpiFix, showing a significantly improved time to healing using the allograft (log-rank P = 0·0110). Cox regression analysis showed that subjects treated with EpiFix had a significantly higher probability of complete healing within 12 weeks (HR: 2·26, 95% confidence interval 1·25-4·10, P = 0·01) versus without EpiFix. These results confirm the advantage of EpiFix allograft as an adjunct to multilayer compression therapy for the treatment of non-healing, full-thickness venous leg ulcers. © 2017 The Authors. International Wound Journal published by Medicalhelplines.com Inc and John Wiley & Sons Ltd. DOI: 10.1111/iwj.12843 PMID: 29024419 [Indexed for MEDLINE]
Appears in following Topics:
Venous Ulcers - Treatment and Prevention
Cellular and/or Tissue Based Products